InhaleRx advances cancer pain and panic disorder trials by Adam Sheldon July 23, 2025July 23, 2025 InhaleRx is on track to dose its first patient in a phase two trial for breakthrough […]
News in brief: Elixinol names new CEO; Aurora flags MedReleaf growth; InhaleRx R&D tax rebate; ODC to ‘share insights’; Tilray appoints new Australian director by Steve Jones June 20, 2025June 26, 2025
News in brief: Tilray launches pastilles; InhaleRx progresses panic disorder trial; NSW calls for hemp plan feedback; BS3 makes key hire by Steve Jones and Martin Lane April 23, 2025April 23, 2025
InhaleRx eyes big pharma deal and ponders product launch through SAS by Steve Jones March 18, 2025March 18, 2025
InhaleRx prepares for pivotal trial in quest to provide relief from breakthrough cancer pain by cannabiz team January 29, 2025January 31, 2025
News in brief: InhaleRx; Hemp Pet; Neurotech International; Cann Group by Martin Lane November 19, 2024April 11, 2025
InhaleRx secures up to $38.5m in funding for clinical trial program by Martin Lane October 18, 2024February 25, 2025
Financial results: Rua Bioscience; Elixinol Wellness; Argent Biopharma; Wellnex Life; InhaleRx; Bioxyne by Martin Lane and Steve Jones September 2, 2024September 3, 2024
Company news: ECS Botanics; Althea; InhaleRx; Neurotech International by Martin Lane and Steve Jones July 10, 2024July 11, 2024
